Skip to main content
Ensol Biosciences Inc. logo

Ensol Biosciences Inc. — Investor Relations & Filings

Ticker · 140610 ISIN · KR7140610007 KO Manufacturing
Open in API
Filings indexed 258 across all filing types
Latest filing 2026-06-04 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 140610

About Ensol Biosciences Inc.

https://www.ensolbio.co.kr/eng/

Ensol Biosciences Inc. is a biopharmaceutical company focused on developing innovative drugs for diseases with limited or no therapeutic alternatives. The company leverages a bio big data and AI-driven platform for its research and development activities. A core area of its technology involves Protein-Protein Interaction (PPI)-regulating short peptide drugs, which are designed for local injection to maximize therapeutic effects and minimize systemic side effects through high specificity and a short half-life in the blood. The company's pipeline targets a range of medical unmet needs, including degenerative disc disease, osteoarthritis, cancer, and neurodegenerative disorders like Alzheimer's disease. Key clinical-stage assets include E1K for osteoarthritis (preparing for Phase 3) and C1K, an anticancer combination therapy (Phase 1).

Recent filings

Filing Released Lang Actions
주요사항보고서(유상증자결정)
Share Issue/Capital Change Classification · 95% confidence The document is a ‘주요사항보고서(유상증자결정)’ filed with the Financial Services Commission/Korea Exchange detailing a paid-in capital increase via third-party allotment. It specifies the number and type of new shares, issuance price, allocation method, schedule, use of proceeds, and related board resolutions. This is an announcement of a new share issuance (capital change), fitting the ‘Share Issue/Capital Change’ (SHA) category.
2026-06-04 Korean
기업설명회(IR)개최결과
Regulatory Filings Classification · 85% confidence The document is a brief regulatory announcement of the holding and results of an investor relations presentation (“기업설명회(IR) 개최 결과”), listing date, time, participants, agenda, and IR material posting details. It does not include substantive financial statements or presentation content itself (so it’s not an Investor Presentation or an interim/annual report). It is therefore a general regulatory filing and best fits the Regulatory Filings (RNS) fallback category.
2026-05-29 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 95% confidence The document is a detailed regulatory filing in Korean pursuant to the Capital Markets Act, reporting large shareholding status and changes of a corporate investor, including exact number of shares, percentages, acquisition methods, and related party details. It corresponds to a major shareholding notification (similar to SEC 13D/13G filings) rather than a financial report, earnings release, or management change. Therefore, it is classified as Major Shareholding Notification.
2026-05-27 Korean
기업설명회(IR)개최
Investor Presentation Classification · 90% confidence The document is a Korean announcement detailing the scheduling, participants, agenda, and logistics for a company’s investor relations presentation (기업설명회(IR)). It is not a formal financial report or earnings release, but rather an invitation/notice for an investor presentation event. Therefore, it falls under the “Investor Presentation” category (Code: IP).
2026-04-29 Korean
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Board/Management Information Classification · 92% confidence The document is a formal regulatory notice titled “사외이사의 선임ㆍ해임 또는 중도퇴임에 관한 신고,” submitted to the Financial Services Commission and Korea Exchange. It details the appointment and dismissal of outside directors, including names, dates, and reasons. This clearly falls under announcements of changes in the company’s board of directors. Therefore, it is classified as Board/Management Information (MANG).
2026-03-26 Korean
주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 80% confidence The document is a formal regulatory disclosure to the Financial Services Commission/Korea Exchange announcing the grant of stock purchase options (“주식매수선택권 부여”). It details the number of options, exercise period, exercise price, fair value calculation, vesting, and related terms—i.e., a capital change via option issuance rather than a full financial or ESG report. There is no evidence of an earnings release, management change, share repurchase, or proxy materials. The closest FIT is category 28 (SHA) for announcements of new share issues or capital changes. Thus, it is best classified as a Share Issue/Capital Change (SHA).
2026-03-26 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.